acetaminophen; oxycodone hydrochloride - Profile

What are the generic drug sources for acetaminophen; oxycodone hydrochloride and what is the scope of patent protection?

Acetaminophen; oxycodone hydrochloride is the generic ingredient in twelve branded drugs marketed by Actavis Elizabeth, Barr, Duramed Pharms Barr, Halsey, Mallinckrodt, Mutual Pharm, Vintage Pharms, Vintage Pharms Llc, Watson Labs, Roxane, Janssen Pharms, Ortho Mcneil Pharm, Abhai Llc, Mikart, Sankalp Lifecare, Specgx Llc, Ph Health, Hikma, Mallinckrodt Inc, Bristol Myers Squibb, Alvogen, Amneal Pharms, Amneal Pharms Ny, Ascent Pharms Inc, Aurolife Pharma Llc, Chartwell, Dr Reddys Labs Sa, Elite Labs Inc, Epic Pharma Llc, Granules, Lannett Co Inc, Nesher Pharms, Novel Labs Inc, Rhodes Pharms, Sanaluz, Sun Pharm Inds Inc, Wes Pharma Inc, and Endo Operations, and is included in sixty-six NDAs. There are twelve patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Acetaminophen; oxycodone hydrochloride has thirty-one patent family members in thirteen countries.

There is one tentative approval for this compound.

Summary for acetaminophen; oxycodone hydrochloride

International Patents:	31
US Patents:	12
Tradenames:	12
Applicants:	38
NDAs:	66
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for acetaminophen; oxycodone hydrochloride

Generic filers with tentative approvals for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		325MG; 7.5MG	TABLET, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for acetaminophen; oxycodone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Elizabeth	OXYCODONE AND ACETAMINOPHEN	acetaminophen; oxycodone hydrochloride	CAPSULE;ORAL	040199-001	Dec 30, 1998		DISCN	No	No
Barr	OXYCODONE AND ACETAMINOPHEN	acetaminophen; oxycodone hydrochloride	CAPSULE;ORAL	040304-001	Oct 2, 2000		DISCN	No	No
Duramed Pharms Barr	OXYCODONE AND ACETAMINOPHEN	acetaminophen; oxycodone hydrochloride	CAPSULE;ORAL	040289-001	Mar 16, 1999		DISCN	No	No
Halsey	OXYCODONE AND ACETAMINOPHEN	acetaminophen; oxycodone hydrochloride	CAPSULE;ORAL	089994-001	May 4, 1989		DISCN	No	No
Mallinckrodt	OXYCODONE AND ACETAMINOPHEN	acetaminophen; oxycodone hydrochloride	CAPSULE;ORAL	040257-001	Aug 4, 1998		DISCN	No	No
Mutual Pharm	OXYCODONE AND ACETAMINOPHEN	acetaminophen; oxycodone hydrochloride	CAPSULE;ORAL	040219-001	Jan 22, 1998		DISCN	No	No
Vintage Pharms	OXYCODONE AND ACETAMINOPHEN	acetaminophen; oxycodone hydrochloride	CAPSULE;ORAL	040106-001	Jul 30, 1996		DISCN	No	No

Expired US Patents for acetaminophen; oxycodone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mallinckrodt Inc	XARTEMIS XR	acetaminophen; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204031-001	Mar 11, 2014	6,488,962

International Patents for acetaminophen; oxycodone hydrochloride

Country	Patent Number	Title	Estimated Expiration
Japan	5897036
Japan	2005507000
Russian Federation	2013132138	СПОСОБЫ ПОЛУЧЕНИЯ СТАБИЛИЗИРОВАННОЙ ТВЁРДОЙ ДОЗИРОВАННОЙ ФОРМЫ ФАРМАЦЕВТИЧЕСКИХ КОМПОЗИЦИЙ, СОДЕРЖАЩИХ МОРФИНАНЫ
Mexico	2013007057	METODOS PARA PRODUCIR COMPOSICIONES FARMACEUTICAS ESTABILIZADAS DE DOSIS SOLIDA QUE CONTIENEN MORFINANOS. (METHODS OF PRODUCING STABILIZED SOLID DOSAGE PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS.)
Canada	2720108	FORMES MEDICAMENTEUSES A LIBERATION ETENDUE DE RETENTION GASTRIQUE COMPRENANT DES COMBINAISONS D'UN ANALGESIQUE NON OPIOIDE ET D'UN ANALGESIQUE OPIOIDE (GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC)
China	103402499	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
World Intellectual Property Organization (WIPO)	2011087765

Investment Scenario and Fundamentals Analysis for Acetaminophen and Oxycodone Hydrochloride

Last updated: February 20, 2026

What are the market fundamentals for acetaminophen?

Acetaminophen, also known as paracetamol, is one of the most used over-the-counter (OTC) analgesic and antipyretic agents globally. It accounts for approximately 20% of OTC analgesic sales in developed countries, with global sales estimated at $2.4 billion annually. Its widespread use is driven by its perceived safety, affordability, and broad indications.

Market size and sales

Region	Estimated Revenue (USD billions)	Growth Rate (Compound Annual Growth Rate, CAGR)	Key Drivers
North America	$1.2	2.1%	OTC accessibility, high prevalence of pain conditions
Europe	$0.7	1.8%	Aging population, OTC preferences
Asia-Pacific	$0.3	4.5%	Increasing healthcare access, urbanization
Rest of World	$0.2	2.0%	Growing demand, regulatory approvals

Market growth is mainly fueled by expanding OTC use and patent expirations leading to increased generic availability. The drug’s safety profile makes it a first-line choice, especially for pediatric and elderly populations.

Regulatory environment

• U.S.: Monitored by the FDA, with guidelines emphasizing safe dosing due to hepatotoxicity risks at high doses.
• Europe: Regulated as a medicinal product with strict labeling and dosage limits.
• Asia: Variable, with some markets imposing restrictions on high-dose formulations to mitigate hepatotoxicity concerns.

Clinical and safety profile

• Effective for mild to moderate pain and fever.
• Risks: hepatotoxicity at doses exceeding recommended levels, especially with alcohol consumption or pre-existing liver conditions.
• Remains the standard comparator in pain relief and fever reduction trials.

What is the investment outlook for oxycodone hydrochloride?

Oxycodone hydrochloride is a semi-synthetic opioid analgesic used for moderate to severe pain. It has a substantial footprint in pain management, especially in the context of post-surgical, cancer, and chronic pain.

Market dynamics

Region	Estimated Revenue (USD billions)	CAGR (2018-2022)	Drivers
North America	$4.2	3.2%	High prescribing rates, opioid-centric pain management
Europe	$1.8	2.5%	Growing opioid use, aging populations
Asia-Pacific	$1.0	8.0%	Emerging demand, regulatory relaxation in some markets
Latin America	$0.4	4.3%	Increased focus on pain management

Regulatory and legal landscape

• United States: Extensive regulation via the Drug Enforcement Administration (DEA). Rescheduling efforts to limit prescription volume and prevent abuse.
• Europe: Tight controls with prescription-only status for opioids.
• Global trends: Increased scrutiny following the opioid crisis. Many jurisdictions have implemented risk mitigation strategies such as tamper-resistant formulations and prescription monitoring programs.

Safety and abuse concerns

• High potential for dependence, abuse, and overdose.
• Regulatory interventions aim to curtail misuse while maintaining clinical access.
• Market is shifting toward abuse-deterrent formulations, which tend to increase development and manufacturing costs but expand market differentiation.

How do patent, generic, and regulatory factors influence investment?

• Acetaminophen: No recent patent protections; marked by high generic competition. Investment centers on manufacturing efficiency and expanding indications (e.g., combination products).
• Oxycodone: Some formulations, such as extended-release versions, benefit from patent protection. Recent patent expirations open markets to generics, though regulatory hurdles and abuse deterrent formulations limit availability.

Patent lifecycle considerations

Drug	Original Patent Expiry	Current Patent Status	Opportunities for Investment
Acetaminophen	N/A	Generics dominant	Brand differentiation, new delivery systems
Oxycodone formulations	2018 (extended-release)	Some patents expired	Development of abuse-deterrent formulas

Pricing and reimbursement environment

• OTC acetaminophen relies on pharmacy and retail channels; pricing pressure is high.
• Prescription oxycodone pricing differs by formulation, with extended-release versions commanding premium prices in certain markets. Reimbursement policies are scrutinized due to abuse concerns.

What are the key risks and considerations for investors?

1. Regulatory risks: Stricter controls and restrictions could diminish market volume, especially for oxycodone.
2. Legal liabilities: Litigation related to opioid use has resulted in significant financial penalties; companies involved in oxycodone manufacturing face ongoing legal challenges.
3. Market saturation: Generic competition limits pricing power for acetaminophen.
4. Public perception: Increased awareness of opioid risks may reduce prescribing and usage.

Key Takeaways

• Acetaminophen remains a staple OTC analgesic with a stable and mature market, primarily driven by generic sales.
• Oxycodone hydrochloride faces decline risks from regulatory restrictions, legal liabilities, and societal pressure against opioids; however, demand persists for severe pain management formulations.
• Investment opportunities may include formulation innovations, abuse-deterrent technologies, and new combination therapies.
• Regulatory and legal landscapes substantially impact market dynamics and valuation, especially in the opioid space.

FAQs

1. Is acetaminophen a good long-term investment?

It has predictable demand due to OTC status and widespread use. Growth is limited due to high generic competition and pricing pressures.

2. How does the opioid epidemic influence oxycodone markets?

Increased regulation and legal action have reduced prescribing and sales volumes, but ongoing demand for pain management sustains certain markets.

3. Are there opportunities in abuse-deterrent formulations?

Yes, companies investing in abuse-deterrent oxycodone formulations may benefit from regulatory support and market differentiation.

4. What are the main legal risks for companies producing opioids?

Litigation for contributing to addiction crises, federal and state investigations, and potential fines can impact financial stability and product lines.

5. How does regulatory variability affect global sales?

Differing approval processes, control measures, and restrictions across jurisdictions influence market access and revenue potential for both drugs.

References

1. FDA. (2022). Acetaminophen use and safety. U.S. Food and Drug Administration.
2. IQVIA. (2022). The Global Use of Pharmacological Pain Management.
3. European Medicines Agency. (2022). Opioid prescribing guidelines and regulations.
4. DEA. (2022). Controlled Substance Schedules and Regulations.
5. MarketResearch.com. (2023). Global Pain Management Drugs Market Outlook.

[1] U.S. Food and Drug Administration. (2022). Acetaminophen use and safety guidelines.
[2] IQVIA. (2022). The global analgesic and pain management market report.
[3] European Medicines Agency. (2022). Regulatory updates on opioid control.
[4] Drug Enforcement Administration. (2022). Controlled Substances Schedules.
[5] MarketResearch.com. (2023). Market analysis of pain management drugs.